Since it was created, more than 30 years ago, quality has always been an integral part of APLUSA’s DNA and is still at the heart of everything we do. Together, our teams collaborated on the journey to achieve ISO 20252:2019 certification. This certification is the result of our commitment to maintain, improve and rewrite APLUSA’s processes. Gaining this certification strengthened our convictions, and helped better clarify our mission and values, reinforcing our strive for excellence in Healthcare Market Research. At APLUSA we believe that client satisfaction, success and innovation are a team effort and joint responsibility where we each play our own unique and important role.
Have fun, stay safe and enjoy life!
Celine Dufrene, Quality & Process Director
What’s Trending these Last Months?
✅ We are ISO certified ✅
APLUSA has obtained ISO 20252-2019 certification for market and opinion research, data analysis, strategic and operational consulting for global healthcare markets, in compliance with applicable regulations, in order to improve the reliability of our clients’ decisions and to contribute to better patient care.
📚 Demand studies 📚
Do You Believe What I Do Or What I Say? The Relentless Pursuit Of Accurate Demand Forecasts presented by APLUSA Bell Falla and EMD Serono during PMRC in May22.
As market researchers and forecasters, a large part of our job is to understand the vagaries of the future market and find ways to bring more precision to estimating future share. In this presentation showcased at PMRC, we review results from several recent demand studies describing methods and their benefits and limitations. Finally, we outline concrete recommendations for improving the dependability of your demand studies.
APLUSA is ISO certified for market and opinion research, data analysis, strategic and operational consulting for global healthcare markets, in compliance with applicable regulations, in order to improve the reliability of our clients’ decisions and to contribute to better patient care.
From 8 to 10th of June 2022 took place the ESCD Congress 2022 in Amsterdam. It provides a forum for experts from around the world to present and discuss cutting-edge issues in Contact Dermatitis but also in Atopic Dermatitis. On this occasion, we are sharing 4 exclusive insights extracted from our AD Syndicated Tool.
INSIGHT 1
Did you know that even among moderate to severe AD patients, 30% are still treated only with topical treatments?
INSIGHT 2
Did you know that COVID-19 significantly accelerated targeted therapies’ uptake, to change the treatment paradigm in moderate to severe AD patients?
INSIGHT 3
Did you know that, when treated with targeted therapy, 8 in 10 moderate to severe AD patients are highly satisfied with it, as observed by physicians?
INSIGHT 4
Did you know that, with targeted therapies prescriptions continuing to be on the rise, the launch of new therapies creates emerging switches between targeted therapies themselves?
Capitalizing on our unique expertise in the AML market and in patient chart-based research, AMLsyndiTrackTM, our AML syndicated study uses real-world data to monitor the evolution of AML management.
Data available from FR, DE, AT, CA, the UK, IT, ES, BE, the NL, CH, SW
We truly think that innovation is a key driver of success, and are happy to promote it through our sponsorship of the Innovative Approach Award, year after year.
Congratulations to the winners this year: Kate Melbourne and Dominique Cummuta from BioVid Corporation!
About the Teams
🎉 APLUS3 in May and June! 🎉
These past months, we were very excited to warmly welcome our three new collaborators within our Lyon offices! Welcome to the team Keltoum, Yasmine and Quentin! 🎉
